In this new project, five european research teams join together with the aim to develop new treatment options for patients suffering from Heart Failure with Preserved Ejection Fraction.
Project start date 06/03/2017
(Kick-off meeting to be held in Rouen, France in September 2017 )
Heart Failure (HF) represents a serious health challenge, with an estimated 6.5 million patients suffering from HF in the European Union, which corresponds to the combined current population of Brussels, Madrid, and Paris. Our collaborative research project, LYMIT-DIS, is aimed at improving diagnosis, prognosis, and development of new treatments for HF, focusing on HF with preserved Ejection Fraction (HFpEF). This type of HF with diastolic cardiac dysfunction, affects more than 50% of HF patients, notably women, and is linked to metabolic syndrome, an increasingly common condition characterized by insulin resistance, abdominal obesity, dyslipidemia, and hypertension.
In this ERA-CVD project, coordinated by Dr. E Brakenhielm, together with 4 european partner teams led by Dr M Van Bilsen (Netherlands), Dr A Ratajska (Poland), Dr E Jones (Belgium), and Dr A Gonzalez-Miqueo (Spain), we will investigate the links between microvascular dysfunction, altered lymphatic transport, and cardiac perfusion/metabolism dysbalance with development of cardiac fibrosis, a hallmark sign of diastolic dysfunction.
The overall objective of LYMIT-DIS is to forward our understanding of the mechanisms involved in the cardiac diastolic dysfunction in HFpEF, with the aim to identify and evaluate innovative treatments to limit the cardiac impact of metabolic syndrome and to prevent the transition from cardiac dysfunction to Heart Failure.